alternative iv lipid emulsions - cdn.ymaws.com · alternative iv lipid emulsions michelle henry,...
TRANSCRIPT
Alternative IV Lipid Emulsions
Michelle Henry, MPH, RD, CNSC Medical Science Liaison, Fresenius Kabi LLC, USA
Oley Conference January 2017
© Copyright Fresenius Kabi AG
• Provide brief background on lipids and their function
• Discuss the evolution of IVLEs
• Discuss the IVLEs approved in the US and their component oils
• Introduce a new alternative lipid emulsion available on the US market
2
© Copyright Fresenius Kabi AG
• Biological substances that are soluble in organic solvents but insoluble in water
Where are they found? • Soybeans/Vegetables
• Walnuts/Peanuts
• Fish
• Avocado/Olives
• Coconuts
• Eggs, milk, animal meats
3
© Copyright Fresenius Kabi AG
• Dense source of energy
• Provides essential fatty acids1,2
• Important in structural components of cell membranes1
• Carry lipid soluble vitamins
• Involved in hormone and enzyme production
• Important in immune and inflammatory responses1
1. Hise M, Brown JC. The ASPEN Adult Nutrition Support Core Curriculum. 2nd Edition, 2012. Silver Springs, MD: American Society for Parenteral and Enteral Nutrition. 2. Escott-Stump S, Dorner S, Grodner M. Nutritional Foundations and Clinical Applications: A Nursing Approach. 6th Edition, 2012. St Louis, Missouri.
4
© Copyright Fresenius Kabi AG
Triglycerides1
• The most abundant lipids in the body
• Fatty acids: the fundamental building blocks of lipids
Phospholipids1
• The components of the lipid bilayer of cell membranes
5 1. Hise M, Brown JC. The ASPEN Adult Nutrition Support Core Curriculum. 2nd Edition, 2012. Silver Springs, MD: American Society for Parenteral and Enteral Nutrition. G
lyce
rol
Hydrophilic polar head group
Hydrophobic non-polar tail
(Extracellular)
(Intracellular)
Phospholipid bilayer
© Copyright Fresenius Kabi AG 6
H3C COOH
Stearic acid (18:0)
H3C COOH
Double bond
Oleic acid (18:1ω-9)
H3C COOH Alpha-Linolenic acid (18:3ω-3)
Double bonds
1 double bond = Monounsaturated Fatty Acids (MUFAs)
2 or more double bonds = Polyunsaturated Fatty Acids (PUFAs)
© Copyright Fresenius Kabi AG
Omega-9 Fatty Acids
Eicosatrienoic Acid (Mead Acid)
20:3 ω9
Oleic Acid (OA) 18:1 ω9
Octadecadienoic Acid 18:2 ω9
Eicosadienoic Acid 20:2 ω9
Arachidonic Acid (AA) 20:4 ω6
Docosapentaenoic Acid 22:5 ω6
Docosatetraenoic Acid 22:4 ω6
24:4 ω6
24:5 ω6
Gamma-Linolenic Acid 18:3 ω6
Dihomo-Gamma-Linolenic Acid 20:3 ω6
Eicosapentaenoic Acid (EPA) 20:5 ω3
Docosahexaenoic Acid (DHA) 22:6 ω3
Docosapentaenoic Acid 22:5 ω3
24:5 ω3
24:6 ω3
Octadecatetraenoic Acid 18:4 ω3
Eicosatetraenoic Acid 20:4 ω3
Arachidonic Acid (AA) 20:4 ω6
Eicosapentaenoic Acid (EPA) 20:5 ω3
Docosahexaenoic Acid (DHA) 22:6 ω3
7
METABOLIC PATHWAYS OF 𝛚-3, 𝛚-6, 𝛚-9 FATTY ACIDS -3, 𝛚-6, 𝛚-9 FATTY ACIDS -6, 𝛚-9 FATTY ACIDS -9 FATTY ACIDS
Adapted from Le HD, et al. Prostaglandins Leukot Essent Fatty Acids. 2009;81:165-170. With permission from Elsevier.
PARENT Essential Fatty Acid PARENT Essential Fatty Acid NON-EFA
elongase
elongase
elongase
Beta-oxidation
delta-6-desaturase
delta-5-desaturase
delta-6-desaturase
elongase
delta-6-desaturase
delta-5-desaturase
Tetraene Triene
© Copyright Fresenius Kabi AG
9 kcal/g
FATTY ACID
Fluidity Receptors Ion Channels
Enzymes Eicosanoids • Prostaglandins • Leukotrienes • Thromboxanes • Protectins • Resolvins • Lipoxins
Cytokines
Immune Cell and Other Cell Types
(Various Functions)
1. Hise M, Brown JC. The ASPEN Adult Nutrition Support Core Curriculum. 2nd Edition, 2012. Silver Springs, MD: American Society for Parenteral and Enteral Nutrition. 8
© Copyright Fresenius Kabi AG
What is an EFA? • An EFA cannot be synthesized by the human body and must therefore be acquired in diet1
• Essential for growth, development, and function2
• Utilized primarily in 3 metabolic pathways3:
Which fatty acids are essential? • Alpha-Linolenic Acid 18:3ω-3
• Linoleic Acid 18:2ω-6
9
1. Wanten G, Calder P. Am J Clin Nutr. 2007;85:1171-1184. 2. Le HD, et al. Prostaglandins Leukot Essent Fatty Acids. 2009;81:165-170. 3. Hise M, Brown JC. The ASPEN Adult Nutrition Support Core Curriculum. 2nd Edition, 2012. Silver Springs, MD: American Society for Parenteral and Enteral Nutrition.
© Copyright Fresenius Kabi AG 11
1. Helfrick FW, et al. J Pediatr 1944;25:400–3. 2. Vanek WV, et al. Nutr in Clin Pract 2012;27:150–92. 3. Osborn HT, et al. Compr Rev Food Sci Food Safety 2002;3:110–20.
Fish oil-containing formulations 2
2005
Fish oil parenteral supplement 2
1998
80% olive, 20% soy2
1996
MCT/LCT emulsions
made of soy and
coconut oil AND
IVLE 50:50 soy oil and safflower oil2
1984
100% soy emulsion became
the first industrially available
IVLE for PN2
1961
Structured mixture of MCT and LCT3
Structured triglyceride
2000
IVLE=intravenous lipid emulsions; PN=parenteral nutrition; MCT=medium-chain triglyceride; LCT=long-chain triglyceride
Cottonseed Oil First IVLE
available, quickly removed for
significant side effects2
1960
© Copyright Fresenius Kabi AG
2010s 2000s 1990s 1980s 1970s 1960s
12
US Approvals
Intralipid (Soybean Oil)
Soybean Oil + Safflower Oil
(Liposyn)
Intralipid (Soybean Oil)
Soybean Oil / Medium-Chain TG
Structured & Physical Mixture
Fish Oil (Omegaven)
Smoflipid®
Soybean Oil + Medium-Chain TG
+ Olive Oil + Fish Oil
Soybean Oil + Medium-Chain TG
Soybean Oil + Olive Oil
Soybean Oil + Medium-Chain
TG + Fish Oil
MCT=medium-chain triglyceride; TG=triglyceride
Soybean oil + MCT +
Olive + Fish oil
Olive oil + soybean oil
Lipomul (Cottonseed Oil)
Pre-1960
Removed from market due to significant side effects in 1960s
No longer available.
Approved, but not
available for purchase.
© Copyright Fresenius Kabi AG
IVLE=intravenous lipid emulsion; MCT=medium chain triglyceride
*Distributed
1. Intralipid Prescribing Information, 2015. 2. Vanek VW, et al. Nutr Clin Pract. 2012;27:150-192. 3. Nutrilipid Prescribing Information 2014, B. Braun Medical, Inc. 4. Clinolipid Prescribing Information, 2013. 5. Smoflipid Prescribing Information 2016.
Intralipid1,2 Nutrilipid3 Clinolipid2,4 Smoflipid5
Manufacturer Fresenius Kabi/ Baxter* B. Braun Medical Baxter Fresenius Kabi
Oil Source Soybean Oil Soybean Oil Olive Oil 80% Soybean Oil 20%
Soybean Oil 30% MCT 30%
Olive Oil 25% Fish Oil 15%
Fat Composition (%, mean values)1-5
Linoleic 53 53 17.9 19.5 α-Linolenic 7.5 7.5 2.4 2.5 Eicosapentaenoic (EPA) 0 0 0 2.3 Docosahexaenoic (DHA) 0 0 0 2.3 α-Tocopherol (mg/L) 38 n/a 32 163-225
© Copyright Fresenius Kabi AG
MCT=medium chain triglyceride
* Not approved in the US
1. Adapted from: Chang MI, et al. Nutrients 2012;4:1828-1850. (Meisel JA, et al. J Ped Surg. 2011;46:666-673). 2. Fresenius Kabi, Data on File.
Intralipid1 Nutrilipid1 Clinolipid1 Smofipid2 Omegaven2*
15
© Copyright Fresenius Kabi AG 16
• Only available IVLE source in the U.S. from 1970 to 2016
• Soybean oil contains an average of: • 50% Linoleic Acid (LA)
• 7% α-linolenic acid (ALA)1
– Prevents EFAD
• High ω-6 fatty acid content: precursors to pro-inflammatory eicosanoids2,3
1. Calder PC. Proc Nutr Soc. 2013;72:263-276. 2. Waitzberg DL, et al. JPEN J Parenter Enteral Nutr, 2006;30(4):351 3. Calder PC. Intensive Care Med; 2010;36(5)375.
© Copyright Fresenius Kabi AG 17
• IVLE with MCT available outside the U.S. since the mid-1980s
• MCT is found in coconut oil and palm kernel oil1
• Good source of energy1 (8 kcal/g) – Provides rapidly available energy2,3
• Efficient triglyceride clearance from bloodstream2
• Have been added to some IVLEs to decrease ω-6 fatty acid1
– Are always mixed with soybean oil for IVLE1 1. Wanten GJ, Calder PC. Am J Clin Nutr. 2007;85:1171-1184. 2. Bach AC, Bayaban VK. Am J Clin Nutr. 1982:36:950-962. 3. Calder PC. Proc Nutr Soc. 2013;72:263-276.
© Copyright Fresenius Kabi AG 18
• IVLE with OO available outside the U.S. since 1990s1
• Provides MUFA, primarily oleic acid1
• Less prone to peroxidation than PUFA2,3
• Not converted into active mediators of inflammatory processes4
• Provides small amounts of linoleic and α-linolenic acid for EFA
1. Calder PC. Proc Nutr Soc. 2013;72:263-276. 2. Wanten GJ. JPEN J Parenter Enteral Nutr. 2015;39 suppl 1:33S-38S. 3. Hise M, Brown JC. Lipids. The ASPEN Adult Nutrition Support Core Curriculum. 2nd Edition, 2012. 4. Waitzberg DL, et al. JPEN J Parenter Enteral Nutr 2006;30:351-367.
© Copyright Fresenius Kabi AG 19
• IVLE with FO available outside the U.S. since mid-1990s
• Very rich in omega-3 fatty acids
• Provides “conditionally essential” fatty acids1-3
– EPA and DHA
• Provides precursors to less inflammatory eicosanoids and specialized pro-resolving mediators4
1. Le HD, et al. Prostaglandins Leukot Essent Fatty Acids 2009; 81:165-170. 2. Kalish BT, et al. JPEN J Parenter Enteral Nutr 2012;36:380-388. 3. Bistrian B. JPEN J Parenter Enteral Nutr 2003;27(3)168-175. 4. Kremmyda LS, et al. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2011;155:195-218.
© Copyright Fresenius Kabi AG
Olive Oil
Soybean Oil
Fish Oil
Medium-Chain
Triglyceride Oil
Safflower Oil
Note: This is a relative (not absolute) figurative scale to demonstrate relative inflammatory activity Vanek VW, et al. Nutr Clin Pract. 2012;27:150-192. 20
© Copyright Fresenius Kabi AG 22
• IV lipid emulsion product made with four different types of oils: Soy, MCT, Olive and Fish
• Provides energy and EFAs
• Safe, well tolerated, and has demonstrated efficacy
Smoflipid is a new lipid IVLE option for adults in the United States
© Copyright Fresenius Kabi AG
Olive Oil (ω-9)
Fish Oil (ω-3)
MCTs
Soy Oil (ω-6)
23 1. Deckelbaum RJ, et al. Biochemistry (Mosc) 1990;29(5):1136-1142; 2. Bach AC, et al. Am J Clin Nutr. 1982;36(5):950-962. 3. Vanek VW, et al. Nutr Clin Pract. 2012;27(2):150-192. 4. Kalish BT, Fallon EM, Puder M. J Parenter Enteral Nutr. 2012; 36:380-8.
• Source of essential fatty acids • Provides energy
• Source of rapidly available energy1
• Clears faster from the bloodstream than other fatty acids2
• Contains small amount of linoleic acid and α-linolenic acid
• Immune neutral3
• Source of conditionally essential fatty acids EPA & DHA4
• Precursors to less inflammatory eicosanoids5
30%
30%
25%
15%
α-tocopherol (approx. 200 mg/L) is an important antioxidant that protects long-chain polyunsaturated fats from peroxidation6.7
5. Kremmyda et al, Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2011. 6. Burrin DG, et al. Adv Nutr. 2014;5(1):82-91. 7. Biesalski HK. Gastroenterology. 2009;137(5 Suppl):S92-S104.
© Copyright Fresenius Kabi AG
IVLE=intravenous lipid emulsion; MCT=medium chain triglyceride *Distributed
1. Intralipid Prescribing Information, 2015. 2. Vanek VW, et al. Nutr Clin Pract. 2012;27:150-192. 3. Nutrilipid Prescribing Information 2014, B. Braun Medical, Inc. 4. Clinolipid Prescribing Information, 2013. 5. Smoflipid Prescribing Information 2016.
Intralipid1,2 Smoflipid5
Manufacturer Fresenius Kabi/ Baxter* Fresenius Kabi
Oil Source Soybean Oil
Soybean Oil 30% MCT 30%
Olive Oil 25% Fish Oil 15%
Fat Composition (%, mean values)1-5
Linoleic 53 19.5 α-Linolenic 7.5 2.5 Eicosapentaenoic (EPA) 0 2.3 Docosahexaenoic (DHA) 0 2.3 Arachadonic (ARA) 0 0.25 α-Tocopherol (mg/L) 38 163-225
© Copyright Fresenius Kabi AG
INDICATIONS AND USAGE • Smoflipid is indicated in adults as a source of calories and essential fatty acids for parenteral nutrition when oral or enteral nutrition is not possible, insufficient, or contraindicated
Limitations of Use
• The omega-6:omega-3 fatty acid ratio and Medium Chain Triglycerides in Smoflipid have not been shown to improve clinical outcomes compared to other intravenous lipid emulsions
• The usual daily dosage is 1 to 2 grams/kg per day and should not exceed 2.5 grams/kg per day
CONTRAINDICATIONS • Known hypersensitivity to fish, egg, soybean, or peanut protein, or to any of the active ingredients or excipients • Severe hyperlipidemia or severe disorders of lipid metabolism with serum triglycerides > 1,000 mg/dL 25
© Copyright Fresenius Kabi AG 26
-------------------------------INDICATIONS AND USAGE----------------------------- Smoflipid is indicated in adults as a source of calories and essential fatty acids for parenteral nutrition when oral or enteral nutrition is not possible, insufficient, or contraindicated. Limitations of Use
The omega-6: omega-3 fatty acid ratio and Medium Chain Triglycerides in Smoflipid have not been shown to improve clinical outcomes compared to other intravenous lipid emulsions. ----------------------------DOSAGE AND ADMINISTRATION--------------------------- For intravenous infusion only into a peripheral or central vein.
The usual daily dosage in adults is 1 to 2 grams/kg per day and should not exceed 2.5 grams/kg per day
WARNING: DEATH IN PRETERM INFANTS See full prescribing information for complete boxed warning.
• Deaths in preterm infants have been reported in literature. • Autopsy findings included intravascular fat accumulation in the lungs. • Preterm and low-birth-weight infants have poor clearance of intravenous lipid emulsion and increased free fatty acid plasma levels following lipid emulsion infusion
© Copyright Fresenius Kabi AG
1. Calder PC, et al. Intensive Care Med 2010;36:735–49 2. Vanek VW, et al. Nutr Clin Pract 2012;27:150-192. 3. Vanek VW, et al. Nutr Clin Pract 2014;29:841. 4. Nutrilipid Prescribing Information 2014, B.Braun
Intralipid1-3 Nutrilipid4 Clinolipid1-3 (ClinOleic outside US) Smoflipid®1-3 Omegaven1-3
Manufacturer Fresenius Kabi/Baxter* B Braun Baxter Fresenius Kabi Fresenius Kabi
Oil Source Soybean Oil Soybean Oil Olive Oil 80% Soybean Oil 20%
Soybean Oil 30% MCT 30%
Olive Oil 25% Fish Oil 15%
Fish Oil 100%
*Distributed
IVLE=intravenous lipid emulsion; MCT=medium-chain triglyceride
28
COMPASSIONATE US USE ONLY